Eli Lilly Files 8-K on Financials and Debt
Ticker: LLY · Form: 8-K · Filed: Feb 6, 2025 · CIK: 59478
| Field | Detail |
|---|---|
| Company | Eli Lilly & Co (LLY) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, debt, filing
TL;DR
Lilly dropped an 8-K detailing its financials and a bunch of debt notes maturing all the way out to 2061.
AI Summary
Eli Lilly and Company filed an 8-K on February 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, detailing various debt instruments such as notes due in 2025, 2026, 2030, 2031, 2033, 2036, 2043, 2049, 2051, and 2061.
Why It Matters
This filing provides investors with an update on Eli Lilly's financial health and its various outstanding debt obligations, which are crucial for assessing the company's financial stability and future borrowing capacity.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate adverse events.
Key Numbers
- 2025 — Notes Due (Maturity date for some of Eli Lilly's debt.)
- 2061 — Notes Due (Maturity date for some of Eli Lilly's longest-term debt.)
Key Players & Entities
- ELI LILLY & Co (company) — Filer
- 0000059478-25-000037 (filing_id) — Accession Number
- 20250206 (date) — Filing Date
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of the results are not provided in the header information.
What is the total amount of debt being disclosed?
The provided text lists various debt instruments with different maturity dates (e.g., notes due June 1, 2025; June 2, 2026; etc.), but the principal amounts for these notes are not specified in this header.
Are there any new debt issuances or significant changes to existing debt?
The filing is an 8-K reporting on financial condition and exhibits, which typically includes information on existing debt, but the header does not specify if there are new issuances or changes.
What is the purpose of filing an 8-K on February 6, 2025?
The 8-K is filed to report on 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits' as of February 6, 2025.
What industry does Eli Lilly & Co. operate in?
Eli Lilly & Co. operates in the 'Pharmaceutical Preparations' industry, with SIC code 2834.
Filing Stats: 612 words · 2 min read · ~2 pages · Grade level 9 · Accepted 2025-02-06 07:05:12
Filing Documents
- lly-20250206.htm (8-K) — 49KB
- q424lillysalesandearningsp.htm (EX-99.1) — 212KB
- logoa31a.jpg (GRAPHIC) — 14KB
- 0000059478-25-000037.txt ( ) — 518KB
- lly-20250206.xsd (EX-101.SCH) — 4KB
- lly-20250206_def.xml (EX-101.DEF) — 19KB
- lly-20250206_lab.xml (EX-101.LAB) — 37KB
- lly-20250206_pre.xml (EX-101.PRE) — 20KB
- lly-20250206_htm.xml (XML) — 10KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing. Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 6, 2025, announcing the financial results of Eli Lilly and Company for the quarter and year ended December 31, 2024.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release of Eli Lilly and Company, dated February 6, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ELI LILLY AND COMPANY (Registrant) By: /s/ Donald A. Zakrowski Name: Donald A. Zakrowski Title: Senior Vice President, Finance, and Chief Accounting Officer Date: February 6, 2025